Sheng Wang

Researcher in pharmacology and structural biology (University of North Carolina at Chapel Hill, based on coauthorship on LSD/psychedelic receptor papers)

Data updated

Papers

5 publications

Trials

0 clinical trials

Research Footprint

Sheng Wang appears in 5 tracked papers (2017–2022), most studied alongside Psilocybin, Ketamine and LSD, across Depressive Disorders, Safety & Risk Management and Chronic Pain.

Most-cited paper: Crystal Structure of an LSD-Bound Human Serotonin Receptor (464 citations).

Frequent co-authors: David Nichols, John McCorvy and Bryan Roth.

Background & Research

Sheng Wang appears to be a researcher in the UNC Chapel Hill pharmacology/structural biology ecosystem and is a coauthor on multiple high-profile receptor-structure papers relevant to psychedelics and neuropsychiatric drug discovery. The publication record strongly links him to work on serotonin receptor structural biology, though the web search did not identify a unique personal faculty page or profile to fully verify his current role.

Key Impact

He is notable for contributing to foundational structural biology work on psychedelic receptors, including an LSD-bound human serotonin receptor structure and structure-based discovery of nonhallucinogenic psychedelic analogs.

5

Research Papers

View publications →

0

Clinical Trials

Explore trials →

Collaboration Network

3 collaborators· click a node to visit their profile

Full network →

Affiliations

Institutions, companies, and organisations Sheng Wang is associated with.